11月21日，科美诊断跌5.22%，成交额5332.56万元。两融数据显示，当日科美诊断获融资买入额594.64 万元，融资偿还547.48万元，融资净买入47.16万元。截至11月21日，科美诊断融资融券余额合计1.65亿 元。 融资方面，科美诊断当日融资买入594.64万元。当前融资余额1.65亿元，占流通市值的5.38%，融资余 额低于近一年30%分位水平，处于低位。 资料显示，科美诊断技术股份有限公司位于北京市海淀区永丰基地丰贤中路7号北科现代制造园孵化楼 一层、六层，成立日期2007年5月10日，上市日期2021年4月9日，公司主营业务涉及临床免疫化学发光 诊断检测试剂和仪器的研发、生产和销售。主营业务收入构成为：LiCA系列产品93.42%，CC系列产品 6.58%。 截至9月30日，科美诊断股东户数1.04万，较上期减少0.60%；人均流通股38586股，较上期增加0.61%。 2025年1月-9月，科美诊断实现营业收入2.61亿元，同比减少24.13%；归母净利润4156.28万元，同比减 少62.94%。 分红方面，科美诊断A股上市后累计派现3.06亿元。近三年，累计派现2.38亿元。 责任 ...

Core Viewpoint - Kemei Diagnostics, established in 2007 and listed in 2021, specializes in clinical immunochemistry and has unique technological advantages in the in vitro diagnostics sector [1] Group 1: Business Performance - In Q3 2025, Kemei Diagnostics reported revenue of 261 million yuan, ranking 25th in the industry, significantly lower than the top competitor's revenue of 3.428 billion yuan [2] - The main business revenue is primarily from LiCA series products, contributing 154 million yuan, accounting for 93.42% of total revenue [2] - The net profit for the same period was 41.56 million yuan, ranking 18th in the industry, but higher than the industry median of 26.19 million yuan [2] Group 2: Financial Ratios - As of Q3 2025, Kemei Diagnostics had a debt-to-asset ratio of 20.50%, which is higher than the industry average of 18.29% [3] - The gross profit margin for the same period was 68.02%, exceeding the industry average of 56.20% [3] Group 3: Executive Compensation - The chairman and general manager, Li Lin, received a salary of 962,200 yuan in 2024, a decrease of 399,400 yuan from the previous year [4] Group 4: Shareholder Information - As of September 30, 2025, the number of A-share shareholders decreased by 0.60% to 10,400 [5] - The average number of circulating A-shares held per shareholder increased by 0.61% to 38,600 [5]

Financial Performance - Total revenue for Q3 2025 was ¥96,206,475.83, a decrease of 18.61% compared to the same period last year[3] - Net profit attributable to shareholders was ¥17,221,945.26, down 51.50% year-over-year[3] - The total profit for the year-to-date period decreased by 63.92% to ¥46,155,660.46[3] - Basic earnings per share for Q3 2025 was ¥0.04, a decline of 55.56% compared to the previous year[3] - The company's revenue for the reporting period was CNY 260.82 million, a year-on-year decrease of 24.13%[12] - Net profit attributable to shareholders was CNY 41.56 million, down 62.94% year-on-year[12] - Total operating revenue for the first three quarters of 2025 was CNY 260,821,861.59, a decrease of 24.1% compared to CNY 343,786,670.77 in the same period of 2024[19] - Net profit for the first three quarters of 2025 was CNY 41,562,776.02, a decline of 63.0% compared to CNY 112,150,960.47 in the same period of 2024[20] - Operating profit for the first three quarters of 2025 was CNY 45,983,456.08, down 64.0% from CNY 128,141,009.06 in the previous year[20] Research and Development - R&D investment totaled ¥20,744,668.54, representing 21.56% of total revenue, an increase of 4.92 percentage points[4] - The company continues to invest in R&D, focusing on innovative products and technologies to meet clinical needs[12] - Research and development expenses increased to CNY 56,428,488.49 in 2025, up 15.0% from CNY 48,830,331.80 in 2024[20] Cash Flow and Assets - The net cash flow from operating activities for the year-to-date period was ¥71,178,778.38, down 47.41% year-over-year[3] - Cash and cash equivalents increased to CNY 648.39 million from CNY 400.25 million as of December 31, 2024[15] - Total current assets decreased to CNY 1,030.99 million from CNY 1,067.68 million[15] - The company's cash flow from operating activities for the first three quarters of 2025 showed a significant change, reflecting ongoing adjustments in operational efficiency[22] - Cash inflow from operating activities for the first three quarters of 2025 was $300.41 million, a decrease of 27% compared to $411.58 million in the same period of 2024[23] - Net cash flow from operating activities for the first three quarters of 2025 was $71.18 million, down 47.4% from $135.33 million in 2024[24] - Total assets at the end of the reporting period were ¥1,771,711,225.11, a decrease of 3.30% from the previous year-end[4] - The company's total assets decreased to CNY 1,771,711,225.11 in 2025 from CNY 1,832,158,296.89 in 2024, a reduction of 3.3%[17] Shareholder Information - The top shareholder, Ningbo Free Trade Zone Yingweili Enterprise Management, holds 26.93% of shares[10] - The company maintained a basic and diluted earnings per share of CNY 0.10 for the first three quarters of 2025, down from CNY 0.28 in the same period of 2024[21] Operational Strategy - The company aims to enhance its product pipeline through a dual strategy of import substitution and clinical interaction[12] - The company holds a leading position with its proprietary LICA® technology platform, emphasizing cost-effective clinical products[12] - The company has a robust strategy to address unmet clinical needs and high-burden disease areas[12] Inventory and Costs - The company has maintained a stable inventory level, with inventory reported at CNY 113.82 million[15] - Total operating costs for the first three quarters of 2025 were CNY 223,690,330.27, down from CNY 234,109,060.40 in the previous year, reflecting a reduction of 4.0%[19] Liabilities and Tax - Total liabilities decreased to CNY 363,165,455.02 in 2025 from CNY 415,851,159.52 in 2024, a decline of 12.6%[17] - The company reported cash outflows for tax payments of $31.77 million in 2025, a decrease from $60.59 million in 2024, representing a reduction of 47.5%[24]

Group 1 - Company announced plans to participate in the 2025 semi-annual performance briefing for the medical device and equipment industry on September 17, 2025 [2]

本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈 述或者重大遗漏，并对其内容的真实性、准确性和完整性依法承担法律责任。 重要内容提示： 会议召开时间：2025年9月17日（星期三）下午 15:00-17:00 证券代码：688468 证券简称：科美诊断 公告编号：2025-020 会议召开地点：上海证券交易所上证路演中心 公司于2025年8月30日在上海证券交易所网站（www.sse.com.cn）发布了《 2025年半年度报告》，为便于广大投资者更全面深入地了解公司2025年半年度的 经营成果、财务状况，公司计划于2025年9月17日下午15:00-17:00参加由上海证 券交易所主办的2025年半年度科创板医疗器械及医疗设备行业集体业绩说明会， 就投资者关心的问题进行交流。 一、说明会类型 （网址：https://roadshow.sseinfo.com/） 会议召开方式：上证路演中心网络文字互动 投资者可于2025年9月16日（星期二）16:00前通过科美诊断技术股份有限 公司（以下简称"公司"）邮箱ir@chemclin.com进行提问。公司将在说明会上 对投资者普遍关注的问题进行回答 ...

Group 1 - The core point of the article is the appointment of Mr. Huang Zhengming as the Vice General Manager of Kemei Diagnostics [2][3]

Group 1 - The core point of the article is the appointment of Mr. Li Lin as the new General Manager of Kemei Diagnostics [2][3]

Group 1 - The company announced the appointment of Ms. Huang Yanling as the Chief Financial Officer and Secretary of the Board [1]

Core Viewpoint - Company announced the appointment of Mr. Li Shiyang as the representative for securities affairs [1] Group 1 - Company made a public announcement regarding the hiring of a new securities affairs representative [1]

Group 1 - The company held its first extraordinary shareholders' meeting of 2025 on September 5, 2025, to elect members of the third board of directors [1] - The newly elected board consists of 6 non-independent directors and 3 independent directors, serving a term of three years [1] - The board members' resumes were disclosed on August 21, 2025, on the Shanghai Stock Exchange website [1] Group 2 - Li Lin was elected as the chairman of the third board of directors, and various committees were formed, including the strategy, audit, nomination, and compensation committees [2] - The audit committee, nomination committee, and compensation committee have a majority of independent directors, with independent directors serving as chairpersons [2] - Liu Ningyue, the chairperson of the audit committee, is a professional accountant [2] Group 3 - Li Lin was appointed as the general manager, Huang Zhengming as the deputy general manager, and Huang Yanling as the financial director and board secretary, with terms aligned with the third board of directors [3] - The qualifications of the appointed senior management personnel comply with relevant laws and regulations [3] - Li Shiyang was appointed as the securities affairs representative to assist the board secretary [3] Group 4 - Contact information for the board secretary and securities affairs representative was provided, including phone number and email address [4]